London Bridge Hospital
27 Tooley Street
London
SE1 2PR
Princess Grace Hospital
London Digestive Centre
Welbeck Street
London
W1G 8DW
The Sloane Hospital
125 Albermarle Road
Beckenham
London
BR3 5HS
t: +44 20 7234 2240
@willalazawi
Non-Alcoholic Fatty Liver
Metabolic-dysfinction associated steatotic liver disease (MASLD) is the new name for non-alcoholic fatty liver (NAFL) and is one of the most common causes of liver disease. People with diabetes, obesity, raised cholesterol, high blood pressure and conditions such as psoriasis are at particular risk, but it also affects many people who do not have these risk factors. It is often only discovered after noticing abnormal liver blood tests and performing appropriate investigations. 10-20% of people with fatty liver have the aggressive form of the disease called steatohepatitis, or MASH for short.
As with other liver diseases, most patients with fatty liver or MASH will not have any symptoms, but without treatment, patients are at risk of progressive liver disease. Although there are no drugs licensed to treat MASH in the UK yet, many new drugs are currently in clinical trials and Professor Alazawi is an internationally recognised research leader in this field.
The cornerstone of treatment is behaviour and lifestyle change focussing on weight loss and exercise. Professor Alazawi is networked with dieticians, physiotherapists and behaviour specialists who can help patients achieve the targets needed to improve liver health and reduce the risk of complications.
